Gracell Biotechnologies Inc. Income Statement

Ask AI

Financial Statements

In millions of CNY; shares in millions, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Revenues
Licensing and collaboration revenue
Expenses
Research and development expenses
Administrative expenses
Loss from operations
Interest income
Interest expense
Other income
Foreign exchange loss, net
Others, net
Loss before income tax
Income tax expense
Net loss
Deemed dividend to convertible redeemable preferred shareholders
Accretion of convertible redeemable preferred shares to redemption value
Net loss attributable to Gracell Biotechnologies Inc.'s ordinary shareholders
Other comprehensive (loss) income
Foreign currency translation adjustments, net of nil tax
Total comprehensive loss attributable to Gracell Biotechnologies Inc.'s ordinary shareholders
Weighted average number of ordinary shares used in per share calculation:
-Basic
-Diluted
Net loss per share attributable to Gracell Biotechnologies Inc.'s ordinary shareholders
-Basic
-Diluted

Comments